Lobbying

Campaign for Sustainable Drug Pricing's latest lobbying report covers Q2 2026, at $50K. The four quarters Q4 2025–Q3 2026 total $150K. Its first report covers Q4 2023; the issues it reports most are Copyright/Patent/Trademark and Medicare/Medicaid.

Campaign for Sustainable Drug Pricing

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$150K
Last 4 quarters
vs last quarter
−100.0%
Q3 2026 against the quarter before
First report
Q4 2023
The first quarter a report named it

Lobbying by quarter

Campaign for Sustainable Drug Pricing lobbying by quarter
Campaign for Sustainable Drug Pricing lobbying by quarter
QuarterAmountReports
Q4 2023$20K1
Q1 2024$20K1
Q2 2024$20K1
Q3 2024$30K1
Q4 2024$30K1
Q1 2025$50K1
Q2 2025$50K1
Q3 2025$50K1
Q4 2025$50K1
Q1 2026$50K1
Q2 2026$50K1
Q3 2026$00

By issue

  • Copyright, patent and trademark$127.5K · 11 reports
  • Medicare and Medicaid$127.5K · 11 reports
  • Pharmacy$127.5K · 11 reports
  • Taxation$37.5K · 3 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • HOUSE OF REPRESENTATIVES11 reports
  • SENATE11 reports

Firms it paid

Firm
Whitmer & Worrall$420K11 quarters

Former officials lobbying for it

Former position
ERIK KOMENDANTLegislative Correspondent, Rep. Zoe Lofgren (CA); Legislative Director, Rep. Jason Altmire (PA); Policy Director, Blue Dog CoalitionQ2 2026
MARTIN WHITMERDeputy CoS-USDOTQ2 2026

Lobbying reports

Filed by
08/05for Q3Endgame StrategiesUnder $5,000
07/22for Q2Whitmer & Worrall$50K
04/21for Q1Whitmer & Worrall$50K
01/21for Q4 2025Whitmer & Worrall$50K
25/10/20for Q3 2025Whitmer & Worrall$50K
25/07/21for Q2 2025Whitmer & Worrall$50K
25/04/21for Q1 2025Whitmer & Worrall$50K
25/02/03for Q4 2024Whitmer & Worrall$30K
24/10/17for Q3 2024Whitmer & Worrall$30K
24/07/18for Q2 2024Whitmer & Worrall$20K
24/05/07for Q1 2024Whitmer & Worrall$20K
24/01/18for Q4 2023Whitmer & Worrall$20K
23/12/04for Q4 2023Whitmer & WorrallUnder $5,000